
According to data from Benzinga Pro, during Q2, Aytu BioScience's (NASDAQ:AYTU) reported sales totaled $23.12 million. Despite a 58.54% increase in earnings, the company posted a loss of $11.55 million. Aytu BioScience collected $21.90 million in revenue during Q1, but reported earnings showed a $27.85 million loss.